David Friedman

David Friedman is a Managing Director at Suvretta Capital Management, LLC, based in New York, where he is responsible for overseeing the firm’s investment strategies and providing leadership in portfolio management. Since joining Suvretta, he has played a pivotal role in guiding the firm’s capital allocation and decision-making processes, frequently representing Suvretta in investment syndicates and on company boards, including a board seat at Avalyn Pharma.

Friedman specializes in investments across the healthcare and biotechnology sectors, leveraging his deep expertise in life sciences. His focus has included identifying high-potential companies in biopharma and healthcare technology, aligning with Suvretta’s active presence as a crossover and public markets investor in these asset classes.

Prior to Suvretta, Friedman was a healthcare analyst at Scopia Capital Management and has extensive experience evaluating innovation-driven companies. He holds an MBA from Harvard Business School, a Doctor of Medicine from the University of Pittsburgh School of Medicine, and a Bachelor of Science in Biology from Duke University, underscoring his unique blend of financial and scientific expertise.